TY  - JOUR
AU  - Nakagawa, Yuko
AU  - Sedukhina, Anna S.
AU  - Okamoto, Naoki
AU  - Nagasawa, Satoi
AU  - Suzuki, Nao
AU  - Ohta, Tomohiko
AU  - Hattori, Hiroyoshi
AU  - Roche-Molina, Marta
AU  - Narvaez, Ana J.
AU  - Jeyasekharan, Anand D.
AU  - Bernal, Juan Antonio
AU  - Sato, Ko
PY  - 2015
SN  - 1949-2553
UR  - http://hdl.handle.net/20.500.12105/5512
AB  - PARP inhibitors are a class of promising anti-cancer drugs, with proven activity in BRCA mutant cancers. However, as with other targeted agents, treatment with PARP inhibitors generates acquired resistance within these tumors. The mechanism of this...
LA  - eng
PB  - Impact Journals
KW  - MULTIPLE-MYELOMA CELLS
KW  - POLY(ADP-RIBOSE) POLYMERASE
KW  - THERAPY
KW  - CANCER
KW  - OLAPARIB
KW  - ACTIVATION
KW  - EXPRESSION
KW  - APOPTOSIS
KW  - PATHWAY
KW  - TARGET
TI  - NF-kappa B signaling mediates acquired resistance after PARP inhibition
TY  - journal article
ER  -